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Senses are our contact to the environment and the eyes are considered the most 
important sensory system. It is known that up to eighty percent of all of our perceptions 
are mediated by the sight1. The human eye is a complex and organized system with a 
high level of specialization2. Also, it is considered an immunological privileged organ 
then, in order to preserve the sight, developed molecular and cellular mechanisms to 
limit the immune response3,4 . 
 
 The retina is a complex anatomic and functionally structure, were the light 
information process starts14. The retina extends back of the eyeball, from the inner 
surface to the ciliary body. It is in contact with the vitreous body internally and with the 
choroid externally15.Eleven layers composed the retina. Starting from the back of the 
eye, we find the RPE, the photoreceptor outer segments (POS), the photoreceptor inner 
segments (IS), the external limiting membrane (ELM), the photoreceptor outer nuclear 
layer (ONL), the outer plexiform layer (OPL), where photoreceptor cells synapse with 
interneurons, the inner nuclear layer (INL), containing bipolar, amacrine and horizontal 
cells, the inner plexiform layer (IPL), where interneurons synapse with the ganglion cell 
layer (GCL), the nerve fiber layer (NFL), and the inner limiting membrane (ILM)16. Due, 
their structural complexity, the retina can be separate in two functional parts: the internal 
part or neural retina and the external part or non-neural retina. The neural retina 
transforms the light into electrical impulses and send it to the brain through the optic 
nerve. The non-neural retina, that that includes RPE and Bruch´s membrane, maintains 
the integrity of the barrier between the choroid and the retina, known as external blood 
retinal barrier (BRB)17.  
 
Retinitis Pigmentosa (RP) is a group of inherited neurodegenerative diseases 
in which rod photoreceptors die due to a genetic mutation, whereas cone photoreceptors 
   
  
disappear secondarily, once rods are gone. While the initial disease symptoms (i.e. night 
blindness) are comparatively mild, the secondary loss of cones ultimately leads to 
complete blindness. The disease affects approximately 1 in 3,000 to 7,000 people 
among the working age population in the developed world51 and is characterized by 
strong genetic heterogeneity with causative mutations in more than 100 genes52. RP was 
described for the first time in 1857 by the ophthalmologist Franciscus Cornelius 
Donders53.  
 
Loss of night vision is the first sign of the disease and normally starts in childhood. 
Afterwards, in the peripheral vision, blind spots appear and tunnel vision is produced 
when these spots merge. The disease progresses affecting the central vision and 
hindering daily tasks, such a reading, driving, and recognizing faces, eventually causing 
blindness in adulthood54. Around 50 to 60% of RP cases show autosomal recessive 
inheritance while 30 to 40% is produced by autosomal dominant heredity. Moreover, 5 
to 15% of RP is produced by X-linked trait55.  
 
In 4 – 8 % of human RP cases, the disease is caused by mutations in genes 
encoding for cGMP specific PDE657,58. The PDE6 family, commonly known as 
photoreceptor phosphodiesterase, entails three genes PDE6A, PDE6B, and PDE6C59, 
encoding a key protein in phototransduction cascade and the intracellular cGMP level 
maintenance60,61. In rods, the PDE6 catalytic core is a heterodimer of PDE6A and B 
subunits, whereas in cones the enzyme consist in two PDE6C subunits giving rise to a 
catalytic homodimer59,61. 
 
A mutation in the B subunit of PDE6 produces a defective protein. The non-
functional enzyme fails to hydrolyze cGMP, causing its accumulation57,62. Notably, 
elevated cGMP levels in dying photoreceptors were found to correlate with increased 
activity of Poly ADP ribose polymerase (PARP)50,63. 
 
 Poly-ADP-ribose (PAR) metabolism is a post-translational modification involved 
in many cellular pathways such as transcription, DNA repair, and cell death64. Although 
the enzyme activity presents beneficial role in cell physiology, PARP is also implicated 
in human diseases such cancer and neurodegenerative disorders. In neurodegenerative 
diseases, including hereditary retinal degeneration, PARP over activation may consume 
cellular substrates, producing a subsequent cell death63,65,66. The precise mechanisms 
leading to cell death remain unknown and no adequate treatment is available. Poly ADP 
   
  
ribose polymerase (PARP) over activity is involved in photoreceptor degeneration and, 
in mice models, its pharmacological inhibition protects the retina.  
 
To date no effective treatments for RP are available53,87. Nutritional supplements 
were used to limit the diseases progression. Among them, Vitamin A, B-carotene, 
Docosahexaenoic Acid (DHA), and lutein, showing a limited effect53. Gene and cell 
therapies are under development53,87,88. In 2018 the food and drug administration (FDA) 
approved the first retina gene therapy for RP65 mutations, that causes LCA and RP. 
Moreover, gene therapy trials for RPGR, PDE6B, MERTK, and RLBP1 mutations are 
currently ongoing53. However, it is expected that gene therapy only halts or slows the 
progression of the disease53 since the absence of long-term benefits were reported, 
probably due to the low transduction efficiency of recombinant gene vectors88. Moreover, 
the use of high dose recombinant gene vectors may produce toxicity88. Cell therapy in 
RP aims to differentiate photoreceptors from stem cells in vitro to replace lost cells and 
restore the vision. The implanted cells should have the capacity  to integrate, survive, 
and signal correctly to bipolar cells53. In RP patients, a bone marrow–derived stem cells 
treatment reported the improvement of quality live 3 months after treatment. 
Unfortunately the treatment efficiency was deteriorated and lost at 12 months87,88.The 
problem seems to be the low transduction efficiency of recombinant gene vectors. 
However, a higher dose produced toxic effects88. 
 
 In advanced stages of RP, retinal prostheses or subretinal implants can be an 
option.  The Argus II Retinal Prosthesis System is available in the USA. In Europe, we 
have the Alpha-IMS (developed in Tübingen University). These implants stimulate the 
visual pathway downstream of the photoreceptors. The visual system restoration is 
modest and rudimental, nevertheless it allows the perception of movement and 
shape53,88. 
 In RP several PARP inhibitors developed for cancer treatments and approved by 
FDA were tested, in vitro and in vivo, in the last years in order to verify its neuroprotective 
capacity in photoreceptors in the rd1 mouse model. PARP inhibitor PJ-34, R503, ABT-
888 (Veliparib) and Olaparib (LynparzaTM) were evaluate in rd1 retinas. Despite PARP 
inhibitors display mechanistic similarities their structural differences affect their pre-
clinical potency and the drug tolerability in patients89. R503 and ABT-888 exhibited 
adverse effects whereas PJ-34 and Olaparib inhibitors shown neuroprotective effects. 
Among this two drugs Olaparib presented stronger photoreceptor protection66 
   
  
Olaparib  is a PARP inhibitor that was initially approved by the FDA in December 
2014 as a monotherapy for ovarian cancer90,91. In addition, it is used in patients with 
metastatic breast cancer92,93 and  is also under clinical trial III in prostate cancer91,94. 
Unlike other PARP inhibitors, Olaparib seems to have multiple way of action. As seen in 
other molecules, Olaparib competes with NAD+, blocking the PAR chains formation by 
PARP90. Additionally, Olaparib inhibits PARP1, PARP2, and PARP3s leading to the 
inability to recruit the appropriate DNA repairing factors. This fact produces the 
accumulation of single strand breaks, followed by the double strand breaks, as well as 
the collapse of replication forks90,91. 
 
 The rd1 and rd10 mice are two animal models that hold a mutation in the gene 
encoding the beta subunit of the PDE675,77, mapped on chromosome 578,79, which protein 
catalyzes cGMP into guanosine monophosphate (GMP)75. Due the mutation, cGMP 
accumulates causing, as a consequence, photoreceptor cell death80. Mice homozygous 
for the rd1 and rd10 mutations79 occur naturally78 and are characterize by rapid 
degeneration rod-like photoreceptor cells, remaining only the cones, which eventually 
die as well.  
 
 Rd1 mice was reported by Kepler for the first time in 192478,81,82. The animal 
carries a murine leukaemia provirus insertion in intron 1 and a second nonsense 
mutation (stop codon) in exon 7. In 2002 Chang et al. described the rd10 mouse that 
contains a missense mutation (R560C) in exon 13 of the PDE6B gene78. Despite both 
mutations occurs at PDE6B there are differences between them. In rd1 mice the protein 
expression and activity remains undetectable whereas in rd10 the PDE6 activity 
decrease significantly, but is detectable at postnatal day (P) 1078,80. Moreover, in rd1 
mice the peak of degeneration occurs before the complete retinal structures 
development at P1350,78. In contrast, in rd10 mice, the peak of rod photoreceptor cell 
death take place when the retina is matured78 at P1850,78. The residual enzyme activity 
in rd10 retinas may reduce the toxic cGMP accumulation at early stage of the disease 
and explain why degeneration is slower in rd10 compared with rd1. Thus, the rd10 is 
considered a better mouse model than rd1 for developing new treatments for RP78,80. 
 
Additionally, retinal cell survival depends of adequate reception and processing 
of the information and appropriate cellular communication. Initially, the extracellular 
vesicles (EVs) were recognized as a mechanism for discharging useless cellular 
components.  
 
   
  
EVs include a heterogeneous group of particles release from cells. Currently, EVs 
are classified in three categories: exosomes, microvesicles or ectosomes and apoptotic 
bodies, based in their biogenesis, mechanism of release, and size96,109. Apoptotic bodies 
are released from the plasma membrane of dying cells, and they have a diameter range 
from 200 nm to 5 mm96. Microvesicles (MVs), or ectosomes, are shed from the plasma 
membrane and their size are between 100-800 nm96. The ectosome nomenclature 
derives from the term ectocytosis used to describe the shedding of vesicles from the 
plasma  membrane in stimulated neutrophils102. Exosomes, which are 30-150 nm in 
diameter, are the EVs best characterized and as explained above their release depends 
of the MBV formation98,109. 
 
The EVs cargo includes nucleic acids, proteins, lipids, and metabolites and can 
be modified depending on the cell type, stimulus, environment, and cell damage. 
Nowadays, the EVs cargo of more than 40 species are studied by more than 1,000 
studies according to the Vesiclepedia127, a community compendium for EVs cargo.  
 
Although the EVs activity in neurodegeneratives diseases is identified, our 
knowledge is the field is still limited150 and there are controversial studies about their 
positive or negative role130,151. Then, EVs were define as a double-edged sword Since 
they can promote the disease progression or they can favour the homeostasis 
maintenance, sequestering neuro-toxic components and therefor protecting the cells 
from degenerate130,151. 
 In the CNS, EVs release was reported in neurons, astrocytes, microglial cells, 
and oligodendrocytes130,150. Many properties were attributed to EVs in the nervous 
system including their role in neural networks development and remodelling130,neuron-
neuron and neuron-glia communication130,147,152,153,regeneration147,152,neuroprotection, 
immunomodulation synaptic plasticity regulation130,147 and vascular integrity147. EVs 
activity was reported in different neurodegeneratives diseases such a Alzheimer’s and 
Parkinson’s Diseases130,150,151,152, Frontotemporal Dementia151  Huntington’s disease  
and Amyotrophic lateral sclerosis130,150, multiple sclerosis150. Moreover, EVs relevance 
was reported in some retinal diseases like dry eye, corneal rejection after transplantation, 
uveitis, AMD, glaucoma154 rhegmatogenous retinal detachment (RRD)149, corneal 
inflamatation and RD148 
 
   
  
Growing evidence has elucidated their roles in cell–cell communication by 
carrying nucleic acids, proteins, and lipids that can, in turn, regulate behavior of target 
cells. Nevertheless, the role of EVs in blinding diseases, such a RP, is far from being 
understood.  
 
As described in other pathologies, the EVs release and cargo are modified in 
retinal diseases, according to the state of the cell and the environment155.  Furthermore, 
EVs can impact the fate of their target or recipient cells. Taking all the information 
exposed into consideration, it is possible that EVs in damaged retinae, such as in RP 
patients, are different from those released from healthy retinae. Thus, the hypothesis 
proposed herein is that retinal EVs released from damaged cells are different in 
terms of number and cargo and they influence their recipient cells. Also, there is 
a connection between PARP and EVs activity in retinitis pigmentosa. 
 
Section from rd1 and rd10 mice and organotypic retinal explants from rd10 were 
used to investigate cellular communication by EVs. CD9 and CD81 tetraspanins were 
studied to investigate EVs activity at tissue level by immunostaining. Inhibition of PARP 
activity was performed using Olaparib. Immunohistochemistry was carried out to 
evaluate PARylated proteins and immunostaining was performed to determinate 
rhodopsin (rho) expression, Müller glia cell activity, and cyclic guanosine monophosphate 
(cGMP) levels after olaparib treatment. Also, inmunofluorescence was used to study EVs 
and their colocalization with cilia in rd10 retinae after PARP inhibition. EVs were isolated 
using ultrafiltration and size exclusion chromatography or a commercial isolation kit, 
depending on downstream applications. Nanosight analysis, electron microscope, 
Fluorescence-Activated Cell Sorting (FACs), dot blot, and proteomics were used to 
characterize the EVs. Moreover, rd10 retinas were treated with EV from wt and vice-
versa.  Inmunostaining assays against CD9, CD81, rho, and IBA-1 (microglia marker) 
were carried out after EVs treatments. TUNEL assay was used to evaluate cell viability, 
thickness, and row photoreceptor number in the outer nuclear layer (ONL) after Olaparib 
and EVs treatments.  
 
EVs release changes with the age in wt mice and also under retinal degeneration 
in rd1 and rd10 in different retinal layers. PARP inhibition by Olaparib rescues 
photoreceptors and also modify the EVs release and cargo in rd10 mice. The EVs release 
was increased in rd10 retinae and the protein cargo was modified under retinal 
degeneration. Moreover, EVs from rd10 retinae had the ability to damage wt retinas and 
   
  
something similar was produced after treated rd10 retinae with EVs from wt. This data 
strongly suggests the implication of EVs in retina development and degeneration.  
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